Effectiveness and safety of 0.5% timolol solution in the treatment of pyogenic granuloma: A randomized, double-blind and placebo-controlled study

Simple item page
dc.contributor.authorPatra, Aparesh Chandraen_US
dc.contributor.authorSil, Amritaen_US
dc.contributor.authorAhmed, Sk. Shahriaren_US
dc.contributor.authorRahaman, Sufiuren_US
dc.contributor.authorMondal, Nasiruddinen_US
dc.contributor.authorRoy, Sudiptaen_US
dc.contributor.authorDatta, Adrijaen_US
dc.contributor.authorKaliyadan, Ferozeen_US
dc.contributor.authorPanda, Saumyaen_US
dc.contributor.authorSetia, Maninder Singhen_US
dc.contributor.authorDogra, Sunilen_US
dc.contributor.authorKhandpur, Sujayen_US
dc.contributor.authorHazra, Avijiten_US
dc.contributor.authorDas, Nilay Kantien_US
dc.date.accessioned2023-08-10T07:29:56Z
dc.date.available2023-08-10T07:29:56Z
dc.date.issued2022-08
dc.description.abstractIntroduction: Pyogenic granulomas are benign vascular lesions of the skin and mucosa which are often a source of concern because of their recurrent bleeding even with minimal trauma. Current treatment for pyogenic granuloma is ablative; no medical therapy is standardized to date. Timolol, due to its vasoconstrictive effect, vascular growth factor inhibition and apoptosis promotion properties, is a potential therapeutic option. Objectives: To assess the effectiveness and safety of topical timolol in the treatment of pyogenic granulomas. Methods: A two-centre, double-blind and placebo-controlled trial (Registration CTRI/2019/04/018581) was conducted. Patients of either sex were recruited with pyogenic granuloma lesions of less than eight weeks duration. Topical treatment with 0.5% timolol or matching glycerin placebo was continued for six weeks. Changes in color, size, bleeding tendency, physicians’ and patients’ global assessments and adverse events were assessed. Results: Forty subjects were randomized between the two groups which were comparable in age, sex, duration of illness and baseline lesion size.Significant improvement was noted with timolol, with color change from first follow-up onwards and lesion size reduction from second follow-up onward. Patients’ assessment of bleeding tendency also showed imrovement from the second visit onward. Between-group comparison showed significant difference with respect to percentage reduction in size (timolol 40.9%, placebo 3.4%; P = 0.002). Rescue treatment (electrosurgery) was required in five patients on placebo and in one in the timolol group (P = 0.182). Complete resolution occurred in 2 (10%) patients with timolol and in no patients on placebo (P = 0.231). Limitations: We observed effects of treatment for only six weeks. Conclusion: Topical timolol may be a treatment option for early pyogenic granulomas but complete resolution is unlikely in six weeks. Studies of longer duration are required to assess resolution and recurrence ratesen_US
dc.identifier.affiliationsDepartment of Dermatology, Bankura Sammilani Medical College, Bankuraen_US
dc.identifier.affiliationsDepartment of Pharmacology, Rampurhat Government Medical College, Rampurhat, Birbhum, West Bengalen_US
dc.identifier.affiliationsDepartment of Dermatology, Medical College, Kolkata, West Bengalen_US
dc.identifier.affiliationsDepartment of Dermatology, Sree Narayana Institute of Medical Sciences, Ernakulam, Keralaen_US
dc.identifier.affiliationsBelle Vue Clinic, Kolkata, West Bengal, 5Consultant Epidemiologist, Mumbaien_US
dc.identifier.affiliationsDepartment of Dermatology, Post Graduate Institute of Medical Education and Research, Chandigarhen_US
dc.identifier.affiliationsDepartment of Dermatology, All India Institute of Medical Sciences, New Delhi, 8Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, Indiaen_US
dc.identifier.citationPatra, Aparesh Chandraen_US
dc.identifier.citationSil, Amritaen_US
dc.identifier.citationAhmed, Sk. Shahriaren_US
dc.identifier.citationRahaman, Sufiuren_US
dc.identifier.citationMondal, Nasiruddinen_US
dc.identifier.citationRoy, Sudiptaen_US
dc.identifier.citationDatta, Adrijaen_US
dc.identifier.citationKaliyadan, Ferozeen_US
dc.identifier.citationPanda, Saumyaen_US
dc.identifier.citationSetia, Maninder Singhen_US
dc.identifier.citationDogra, Sunilen_US
dc.identifier.citationKhandpur, Sujayen_US
dc.identifier.citationHazra, Avijiten_US
dc.identifier.citationDas, Nilay Kanti. Effectiveness and safety of 0.5% timolol solution in the treatment of pyogenic granuloma: A randomized, double-blind and placebo-controlled study. Indian Journal of Dermatology, Venereology and Leprology. 2022 Aug; 88(4): 500-508en_US
dc.identifier.issn0973-3922
dc.identifier.issn0378-6323
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/222996
dc.languageenen_US
dc.publisherScientific Scholaren_US
dc.relation.issuenumber4en_US
dc.relation.volume88en_US
dc.source.urihttps://doi.org/10.25259/IJDVL_565_20en_US
dc.subjectPyogenic granulomaen_US
dc.subjectrandomized controlled trialen_US
dc.subjecttimololen_US
dc.titleEffectiveness and safety of 0.5% timolol solution in the treatment of pyogenic granuloma: A randomized, double-blind and placebo-controlled studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJDVL2022v88n4p500.pdf
Size:
7.64 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Dermatology, Venereology and Leprology